4//SEC Filing
Bruns Ingmar 4
Accession 0001725160-24-000190
CIK 0001725160other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 7:02 PM ET
Size
5.8 KB
Accession
0001725160-24-000190
Insider Transaction Report
Form 4
Bruns Ingmar
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-12-02+712,650→ 712,650 totalExercise: $3.66Exp: 2034-12-02→ Common Stock (712,650 underlying)
Footnotes (1)
- [F1]The options will vest over a four-year period as follows: 25% of the options will vest on November 13, 2025, with the remaining 75% vesting in substantially equal monthly installments thereafter until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001838041
Filing Metadata
- Form type
- 4
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 7:02 PM ET
- Size
- 5.8 KB